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Abstract: The clinical importance of microparticles resulting from vesiculation of platelets 
and other blood cells is increasingly recognized, although no standardized method exists for 
their measurement. Only a few studies have examined the analytical and preanalytical steps and 
variables affecting microparticle detection. We focused our analysis on microparticle detection 
by flow cytometry. The goal of our study was to analyze the effects of different centrifugation 
protocols looking at different durations of high and low centrifugation speeds. We also ana-
lyzed the effect of filtration of buffer and long-term freezing on microparticle quantification, as 
well as the role of Annexin V in the detection of microparticles. Absolute and platelet-derived 
microparticles were 10- to 15-fold higher using initial lower centrifugation speeds at 1500 × g 
compared with protocols using centrifugation speeds at 5000 × g (P , 0.01). A clear   separation 
between true events and background noise was only achieved using higher centrifugation speeds. 
Filtration of buffer with a 0.2 µm filter reduced a significant amount of background noise. Storing 
samples for microparticle detection at −80°C decreased microparticle levels at days 28, 42, and 
56 (P , 0.05 for all comparisons with fresh samples). We believe that staining with Annexin V 
is necessary to distinguish true events from cell debris or precipitates. Buffers should be filtered 
and fresh samples should be analyzed, or storage periods will have to be standardized. Higher 
centrifugation speeds should be used to minimize contamination by smaller size platelets.
Keywords: circulating microparticles, detection method, flow cytometry
Introduction
Microparticles have been shown to be universal markers of activation, cell injury, or 
apoptosis in eukaryotic cells.1 In addition, microparticles have diagnostic and func-
tional roles, especially as mediators of cellular interactions, such as inflammation or 
coagulation.1–3 The clinical importance of microparticles is being increasingly recog-
nized, although no standardized method exists for their measurement.
These vesicles are the product of exocytic budding and consist of cytoplasmic 
components and phospholipids. During microparticle release, the normal asymmetric 
distribution of phospholipids between the two leaflets of the plasma membrane is lost, 
resulting in phospholipid exposure.1 Typically, microparticles are smaller than 1.0 µm, 
expose the anionic phospholipid phosphatidylserine on the outer leaflet of their mem-
brane, and carry surface membrane antigens reflecting their cell of origin, including those 
induced by cellular activation, cell injury, or apoptosis.4 These properties permit detec-
tion of specific subpopulations, such as endothelial or platelet-derived   microparticles.5 
Different subpopulations of microparticles have already been found to be of clinical 
significance in various vascular disorders.6 Because there is no uniform consensus Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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regarding the definition and detection of   microparticles, the 
levels of microparticles depend on the detection technique, 
which makes it difficult to compare results across different 
studies. Therefore, optimization and standardization of detec-
tion methods are important to define microparticles correctly 
and to avoid falsely high or low quantification.
Only a few studies have examined how levels of micropar-
ticles are affected by analytical and also preanalytical steps 
and variables. Some studies have looked at preanalytical 
variables, including blood sampling, anticoagulation in 
collection tubes,7 needle size,7 and thawing temperature.8 
Other investigators have studied the effect of centrifuga-
tion protocols on microparticle detection,7 use of isotype 
controls for flow cytometry,9 and use of calibrated beads for 
microparticle detection.10
The goal of our study was to optimize further the 
method of flow cytometry for detection of microparticles 
and facilitate standardization of protocols. We analyzed the 
effects of different centrifugation protocols, filtration of 
buffer, and long-term freezing on microparticle quantifica-
tion in healthy controls. In addition, we analyzed the role 
of Annexin V in the detection of microparticles. Ideally, 
the true level of microparticles should be detected and 
microparticles should be distinguishable from cell debris 
or other precipitates.
Materials and methods
Blood samples
The optimization of microparticle detection was performed 
using healthy controls. Written informed consent was 
obtained from 10 healthy donors (six female and four male 
donors) under a study protocol approved by the local Institu-
tional Review Board. Citrated blood (18 mL) was collected 
in an atraumatic fashion using a 21-gauge needle. The first 
3 mL were discarded. The samples were processed within 
two hours.
Preparation of platelet-poor plasma
Platelet-poor plasma was obtained using three different cen-
trifugation protocols (Table 1). Each centrifugation protocol 
included two steps. The initial step for protocol 1 consisted 
of two centrifugations at 5000 × g for five minutes at room 
temperature. After the first centrifugation at 5000 × g for five 
minutes, the supernatant was transferred into a new tube, 
leaving 200 µL above the cell pellet, and was centrifuged 
again for five minutes at 5000 × g. In protocol 2, platelet-poor 
plasma was obtained by an initial single centrifugation at 
5000 × g for 15 minutes, and in protocol 3 by centrifugation 
at 1500 × g for 15 minutes. After centrifugation, the super-
natant was transferred into a new tube, while discarding the 
last 500 µL at the base of the centrifuged tube. Aliquots of 
500 µL were stored at −80°C. After thawing quickly at 37°C, 
a microparticle pellet was obtained from the platelet-poor 
plasma by a second centrifugation step at 17,000 × g for 
either 20 or two minutes. Subsequently, the supernatant was 
discarded and the microparticle pellet was reconstituted in 
Annexin V buffer (Becton Dickinson, Franklin Lakes, NJ) 
at 4°C. All buffers were sterile-filtered with a 0.2 µm filter 
(Whatman, Piscataway, NJ).
Labeling with antibodies and Annexin V
The purpose of this study was not to analyze different panels 
of surface markers to define the cellular origin of micropar-
ticles. Therefore, we focused on two different surface 
markers or combinations to define endothelial-/leukocyte-
derived microparticles (CD31+/CD42−) and platelet-derived 
microparticles (CD31+/CD42a+), especially as platelet-
derived microparticles are the most common microparticles 
found in the circulating blood.
After obtaining a microparticle pellet from platelet-poor 
plasma, this isolated microparticle pellet was resuspended in 
440 µL Annexin V binding buffer (diluted 1:10 in distilled 
water). All buffers were sterile-filtered with 0.2 µm filter 
(Whatman). 60 µL Annexin V-fluorescein   isothiocyanate 
(diluted 1:10 in Annexin V binding buffer) was added. A 
  volume of 40 µL microparticle-Annexin suspension was 
labeled with 10 µL of fluorescent antibodies phycoerythrin 
(PE)-conjugated CD31 (Becton Dickinson) and peridinin-
  chlorophyll-protein (PerCP) complex-conjugated CD42a 
(Becton Dickinson diluted in phosphate-buffered saline with-
out CaCl2 and MgCl2 [14190–094; Gibco, Billings, MT] 1:3). 
TruCount tubes (Becton Dickinson) with a known number of 
fluorescent beads were utilized for quantification containing 
40 µL of Annexin-fluorescein isothiocyanate (FITC)-labeled 
microparticle suspension.
Table 1 Three different centrifugation protocols used to detect 
microparticles
Protocol Step 1 Step 2
1 5.000 × g; 17.000 × g; 17.000 × g;
2 × 5 min at 20°c 20 min at 4°c 2 min at 4°c
2 5.000 × g; 17.000 × g; 17.000 × g;
1 × 15 min at 20°c 20 min at 4°c 2 min at 4°c
3 1.500 × g; 17.000 × g; 17.000 × g;
1 × 15 min at 20°c 20 min at 4°c 2 min at 4°cVascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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events in region containing cell
events in region containing absolute count beads
×
 beads per TruCount- tube
test volume in µL
= absolute count of microparticle/µL
The samples were incubated for 15 minutes in the dark at 
room temperature, then diluted in 200 µL of Annexin V bind-
ing buffer and immediately analyzed on a Becton Dickinson 
FACSCanto with the appropriate software (FACSDiva).
Microparticle enumeration  
by flow cytometry
For the detection of microparticles by flow cytometry, 
an initial microparticle-size gate was set with the help of 
calibrating fluorescent 0.8 µm and 3.0 µm latex beads 
(Sigma, St. Louis, MO). This microparticle gate excludes the 
electronic background noise through the threshold. In parallel, 
we used Megamix (American Diagnostic, Hauppauge, NY), 
a mixture of microbeads of three different sizes (0.5 µm, 
0.9 µm, and 3.0 µm) which was developed to confirm the 
size of the microparticles.
Forward scatter and side scatter had a logarithmic gain. 
The absolute count of microparticles was measured setting the 
stop condition for TruCount beads at 10,000 events. In order 
to separate true events from background noise and unspecific 
binding of antibodies to debris, we defined microparticles as 
particles that were less than 1.0 µm in diameter, had positive 
staining for Annexin V , and expressed surface antigens (CD31 
or CD42, or both). Because isotype controls may generate 
falsely negative or positive microparticles,9 we evaluated the 
background by using a control in which all stains were used, 
except for the two colors of interest. This is a modified version 
of the technique named “fluorescence minus one”.11,12
Filtration
Samples from the 10 healthy donors were analyzed with sterile-
filtered and nonsterile-filtered Annexin V buffer. Microparticle 
detection was compared using these two different filter settings. 
Briefly, Annexin V buffer was diluted in distilled water 1:10. 
After dilution, the whole suspension was sterile-filtered with 
a 0.2 µm filter (Whatman) or remained unfiltered. Afterwards, 
the centrifugation protocols 1, 2, and 3 were applied to measure 
the effect of filtration on microparticle detection.
storage
In order to analyze the effect of freezing, microparticle 
pellets were obtained and analyzed from fresh and frozen 
samples of six healthy donors. To study the effect of   different 
storage durations at −80°C, the samples were analyzed 
immediately and after 24 hours, and then after two, four, six, 
and eight weeks of freezing in separate individual aliquots. 
Again, after thawing quickly at 37°C, a microparticle pellet 
was obtained by a second centrifugation step of 17,000 × g 
for 20 minutes. Subsequently the supernatant was discarded 
and the microparticle pellet was reconstituted in Annexin V 
buffer (Becton Dickinson) at 4°C.
statistics
Statistical analysis was carried out using MedCalc software 
(MedCalc, Mariakerke, Belgium) by applying the Kolmogorov–
Smirnov procedure for testing a normal distribution and the 
paired t-test for testing significant differences between levels 
of microparticles. Results are expressed as mean ± standard 
deviation.
Results
Detection of circulating microparticles
Figure 1 demonstrates the detection of circulating micropar-
ticles. The microparticle size gate was set with the help of 
fluorescent 0.8 µm and 3.0 µm latex beads. Microparticles 
were identified by size and Annexin V-  fluorescein isothiocya-
nate labeling. TruCount beads were used for quantification. 
Microparticles were defined as particles that were less than 
1.0 µm in diameter, had positive staining for Annexin V , and 
expressed surface antigens (CD31 or CD42, or both).
centrifugation
The effect of centrifugation on detection and quantification of 
microparticles was analyzed comparing three different cen-
trifugation protocols (Table 1). In all protocols, the majority 
of detected microparticles were of platelet origin (CD31+/
CD42a+). Endothelial-/leukocyte-derived microparticles 
(CD31+/CD42a−) were found 50 to 100 times less often. All 
microparticle values are shown in Table 2. The absolute amount 
of microparticles was not significantly different comparing 
centrifugation protocol 1 (mean 608 ± 244 microparticles/µL) 
and 2 (mean 870 ± 390 microparticles/µL, P = 0.1318) 
using the second centrifugation step for 20   minutes. In 
contrast, protocol 3 showed significantly higher absolute 
microparticle counts when compared with either protocol 
1 or 2 (mean 7928 ± 3894 microparticles/µL, P , 0.0006, 
see Figure 2a and Table 2). With an initial centrifugation at 
1500 × g (protocol 3) we also detected a 10- to 15-fold higher 
amount of platelet-derived microparticles compared with the Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  protocols with an initial centrifugation at 5000 × g (Table 2). 
There was no significant increase in endothelial-/leukocyte-
derived microparticles using protocol 3 (P . 0.05).
Using different durations of centrifugation for the   second 
step (two versus 20 minutes) did not have an effect on the 
levels of microparticles. No significant differences in abso-
lute numbers of microparticles were found in   protocol 1 
(mean 502 ± 384 microparticles/µL, P = 0.1563), protocol 2 
(mean 985 ± 467 microparticles/µL, P = 0.0767) and protocol 
3 (mean 9379 ± 3909 microparticles/µL, P = 0.0899) com-
paring the duration of 2 versus 20 minutes. Similarly, there 
were no significant differences comparing platelet-derived 
microparticles (P . 0.05 for comparisons between the three 
groups) or endothelial-/leukocyte-derived microparticles 
(P . 0.05 for comparisons between the three groups).
The dot plots for the different centrifugation protocols 
are shown in Figure 2b. These dot plots showed a very 
clear separation between true events and background noise 
in protocols 1 and 2, whereas protocol 3 led to a less clear 
separation and increased background signals.
Filtration
Current detection techniques for microparticles, such as stan-
dard flow cytometry, have a detection threshold of 0.4–0.5 µm. 
The analysis of these small particles remains challenging 
regarding a clear distinction between microparticles and 
unspecific precipitates. Therefore, we investigated whether 
filtration of the buffers and solutions used for microparticle 
detection had any influence on background and total numbers. 
Figure 3 demonstrates that filtration of buffer with a 0.2 µm 
filter reduced a significant amount of background noise, cell 
debris, and precipitates, which have the same size range as 
microparticles and could influence or disturb the analysis. 
Therefore, the results of the storage and centrifugation experi-
ments presented are those in which filtered buffer is used.
storage
The effect of storage was analyzed by obtaining micropar-
ticles pellets from fresh and frozen samples (Figure 4). 
Compared with freshly analyzed samples at day 0 (mean 
3798 ± 2400 microparticles/µL), the total amount of 
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Figure 1 Detection of circulating microparticles. The microparticle gate was set according to Annexin V binding and size. Particle size was determined by 0.8  µm and 3.0 µm 
latex beads (beads not shown). TruCount beads were used for quantification (see upper right corner).
Table 2 MP distribution in centrifugation protocol 1 to 3
Antigen markers Protocol 1 Protocol 2 Protocol 3
20 min 2 min 20 min 2 min 20 min 2 min
MP number per µL plasma 608 ± 244 502 ± 384 870 ± 390 985 ± 467 7928 ± 3894 9372 ± 3909
cD42+/cD31+ per µL plasma 467 ± 175 328 ± 164 709 ± 335 733 ± 389 7662 ± 3793 9089 ±  3863
cD42−/cD31+ per µL plasma   10 ± 13   6 ± 10   5 ± 5   9 ± 20   18 ± 24   13 ± 23Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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(mean 562 ± 310 microparticles/µL, P = 0.0392), the value 
decreased even below the ones measured at day 0 in the fresh 
sample (fresh sample mean 3798 ± 2400 microparticles/µL, 
P = 0.0186 compared with sample after 56 days).
Discussion
A wide variety of different methods are used to measure, 
quantify, and phenotype microparticles from blood samples, 
other body fluids, or cell culture supernatants.13,1 The small 
size of microparticles may hamper accurate measure-
ment using currently available detection techniques. Flow 
cytometry is widely used to detect microparticles, but 
there is no consensus on the protocol of sample process-
ing. Because the clinical importance of microparticles is 
increasingly being recognized, it is crucial to standardize 
methods to allow comparison of data across different stud-
ies. Microparticles appear close to the electronic noise and 
may interfere with cellular debris and precipitates. Emerging 
evidence suggests that some microparticles are even less 
than 0.4 µm in size, and current detection techniques, such 
as standard flow cytometry, have a detection threshold in 
the range 0.4–0.5 µm.14 Levels of microparticles can also 
be affected by many sample processing steps, ranging from 
collection of blood, centrifugation of samples, storing of 
microparticle pellets, to staining of phospholipids and surface 
membrane antigens for determining the cell of origin of the 
microparticle.7,13
The impact of preanalytical steps, like the collection of 
blood samples, has already been analyzed and discussed 
by other investigators.7,8 It is recommended to collect 
samples in an atraumatic fashion with larger needles to avoid 
sheer stress and endothelial activation. Also, citrate tubes 
should be preferred over ethylenediamine tetraacetic acid, 
because the latter is known to interfere with microparticle 
measurements.7
One focus of our study was to analyze the effect of differ-
ent centrifugation protocols on microparticle   measurements. 
Most investigators use two steps for centrifugation.15 The 
first centrifugation step(s) leads to platelet-poor plasma, 
removing cells, especially platelets and erythrocytes from the 
blood samples. Some investigators use a second centrifuga-
tion step to isolate a microparticle pellet,15 and others detect 
  microparticles directly from the platelet-poor plasma to 
prevent loss of microparticles.15,16 The latter authors feel that 
microparticles might be lost because the final supernatant is 
discarded and microparticles are measured in the resuspended 
pellet.17 It remains controversial as to which technique should 
be applied. We compared three different centrifugation 
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Annexin V-positive microparticles increased after storage 
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protocols that have been in line with published protocols 
(Table 3).15 All three centrifugation protocols applied in our 
study have primarily yielded platelet-derived microparticles, 
which is consistent with several previous studies.18–20 In par-
ticular, the lower centrifugation speed of 1500 × g used in our 
study yielded a 10- to 15-fold increase in the absolute numbers 
of platelet-derived microparticles. One group   demonstrated 
cellular   contamination by platelets and red blood cells to 
be responsible for a higher amount of microparticles when 
comparing different centrifugation protocols.7 It is also highly 
possible that a significant amount of those platelet-derived 
microparticles derived during the analytical process, eg, 
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activation of platelets, can still occur ex vivo with release of 
microparticles. Dot plots of the three different centrifugation 
protocols in our study (Figure 2b) demonstrated that a clear 
separation between true events and background noise is only 
possible with a higher initial centrifugation speed (5000 × g, 
protocols 1 and 2). These findings suggest that more cell 
debris, precipitates, and irrelevant cellular elements at lower 
centrifugation speed may disturb the analysis. Although anti-
bodies like CD31 seem to bind to these elements, unspecific 
binding of the antibodies cannot be ruled out without using 
a membrane marker to determine the cellular origin. Higher 
numbers of platelet-derived microparticles could also mask 
other subgroup of microparticles which are small in numbers, 
such as endothelial-/leukocyte-derived microparticles. This is 
supported by our study because the small fraction of micropar-
ticles of endothelial/leukocyte origin (CD31+/CD41−) did not 
increase significantly using the lower centrifugation speed in 
contrast with platelet-derived microparticles. However, others 
found higher numbers of endothelial-derived microparticles 
with different centrifugation protocols, either by using a 
four-step centrifugation protocol with low centrifugation 
speeds7 or by decreasing the time of the second centrifugation 
step.7 Analysis of these subgroups of microparticles needs to 
be performed in more detail in future studies.
We also looked at the time of centrifugation. We compared 
two minutes versus 20 minutes at 17,000 × g for the second 
centrifugation step. The results were not   significantly different. 
Some authors have found that shorter centrifugation facili-
tates detection of endothelial-derived   microparticles.7 We 
could not confirm this finding. The absolute numbers of 
endothelial-/leukocyte-derived microparticles did not differ 
significantly in our three   protocols. The same is true for 
platelet-derived microparticles. We conclude that shorter 
durations of the second centrifugation step are practicable 
because it shortens the analysis and simplifies the protocol 
for clinical use.
It is common practice to freeze platelet-poor plasma or 
supernatant after the initial centrifugation step, and then 
store the samples and continue with the analysis at a later 
time point. Trummer et al looked at three different thawing 
procedures and their effect on microparticle levels.8 They 
concluded that thawing of snap-frozen, platelet-free plasma 
samples should be carried out at room temperature or at 37°C 
in a water bath, but not on ice. Shah et al7 analyzed the effect 
of storage on microparticle detection in a systematic fashion. 
A significant decrease of microparticle levels after four weeks 
was found. They failed to prove that protease inhibitors could 
prevent this decline. Others have only mentioned that they 
did not find an effect of freezing.21,22 Some investigators 
even picked samples from their studies randomly and tested 
microparticle counts before and after freezing, and did not 
find any differences.23 We could demonstrate that, after an ini-
tial rise in microparticle levels, the decline of microparticles 
continues over eight weeks. The microparticles are even lower 
in numbers after eight weeks compared to the initial counts. 
Xiao et al showed that freezing itself generates microparticles 
initially, although they did not perform a long-term follow-up 
study.24 We also compared different freezing techniques by 
mixing plasma with either dimethyl sulfoxide (7.5%) or 
HEPES buffer before freezing, and performed either snap 
freezing in liquid nitrogen or freezing samples at −80°C (data 
not shown). These measurements did not prevent the decline 
in microparticle numbers over time.
Despite the fact that protease inhibitors did not prevent 
decline of microparticles after freezing, it is still possible 
for proteases to be activated and disrupt the microparticle 
vesicles after freezing is initiated. This may initially gener-
ate higher numbers of microparticles. It is possible that once 
the proteases have digested the microparticles into smaller 
pieces, it becomes impossible to measure them accurately 
because they may no longer be Annexin-positive. Ideally, 
microparticles should be analyzed from fresh samples or 
Table 3 Different published centrifugation protocols for detection of MP
Authors Technique Centrifugation step I Centrifugation step 2 MP detected
Biró et al33,34 Flow cytometry 1550 × g, 20 min 18,000 × g, 30 pellet
Brogan et al31,34 Flow cytometry 5.000 × g, 5 min 17,000 × g, 20 pellet
Dignat-george et al17 Flow cytometry 1500 × g, 15 min 13,000 × g, 2 plasma
enjeti et al33 Flow cytometry 1500 × g, 30 min 13,000 × g, 2 plasma
Jimenez et al 34 Flow cytometry 200 × g, 10 min 1500 × g, 20 min plasma
nomura et al33 eLisA 1500 × g, 20 min none plasma
shah et al7,32 Flow cytometry 160 × g, 20 min 13,000 × g, 2 min pellet
1500 × g, 20 min
shet et al13 Flow cytometry 13,000 × g, 10 min 100,000 × g, 60 pellet
Abbreviations: MP, microparticles; eLisA, enzyme-linked immunosorbent assay.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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shortly after onset of storage, eg, 14–28 days. If frozen 
samples are used, the storage time should be the same, eg, 
all samples are analyzed 14 days after onset of storage. The 
same was true for serial samples in one patient. Neverthe-
less, using only fresh samples is highly labor-intensive, can 
complicate interinstitutional collaboration, and decreases 
laboratory performance.
It is also controversial whether staining for phospholipids 
with Annexin V should be performed. Some groups define 
microparticles only by size and surface antigen staining 
without testing for Annexin V positivity.18,22,25,26 In addition, 
the existence of “Annexin-negative microparticles” has 
been suggested earlier. Endothelial- and monocyte-derived 
microparticles, and not platelet-derived microparticles, that 
are either detected or not by Annexin V , have been described 
in patients with sickle cell disease.22 It has been reported 
that the concentration of microparticles (without the use 
of Annexin staining) is 30 times higher than the concentra-
tion of microparticles that are detected by Annexin V .27 We 
could demonstrate that simply analyzing unfiltered buffer 
resulted in a significant amount of background noise, cell 
debris, and precipitates, which have the same size range as 
microparticles. This could influence and disturb the analysis 
and quantify false-positive microparticles. In our opinion, 
positive staining for Annexin V has to be applied as one crite-
rion to define microparticles in order to be able to distinguish 
true events from cell debris or precipitates.
On a different note, other staining for phospholipids, 
such as bio-maleimide, has been analyzed and found to 
be comparable with Annexin V regarding platelet-derived 
microparticles.16 However, we could not confirm this find-
ing (data not shown). Its potential role as another marker 
for microparticles remains to be analyzed further. Ulex 
europaeus is another marker which could be used to detect 
endothelial microparticles, nevertheless it may bind to other 
plasma constituents, thereby making it less specific.27
It is also crucial to use the appropriate negative   controls. 
One group looked at the diversity in staining intensity 
of   isotype controls as a potential source of error in the 
characterization and quantification of microparticles by 
flow cytometry. They suggest the use of antigen-negative 
microparticles to adjust instrument settings.9 In our opinion, 
controls and flow cytometry data, eg, dot plots, should be 
provided to compare results between different groups and 
serve as quality standards. Another important aspect is that 
flow cytometry should be performed by highly skilled experts 
in specialized laboratories, which could limit widespread use 
of this laboratory technique.28
The purpose of this study was not to analyze   different 
  panels of surface markers to define the cellular origin of 
microparticles. Other groups have already shown that 
standardization is needed to quantify different types of 
microparticles. Van Ierssel et al demonstrated that the amount 
of endothelial microparticles counted was different for each 
phenotypic subset examined.29 Other techniques, such as plot-
ting fluorescence intensities for measuring platelet-derived 
microparticles against a calibration curve or using a blend of 
size-calibrated fluorescent beads in a fixed numeric ratio, are 
used to standardize measurements of microparticles.30 Future 
studies are needed to optimize the measurement of micropar-
ticles of different origin and size. Another area is to find a 
potential alternative to Annexin V as a membrane marker.
In summary, we feel strongly that staining with Annexin V 
is necessary at this point in time to distinguish true events 
from cell debris or precipitates, bearing in mind that a sig-
nificant amount of microparticles might not be detected. 
Buffers should be filtered and the samples should be analyzed 
either freshly or should be stored for the same duration. The 
centrifugation protocol should consist of two steps. The first 
step to obtain platelet-poor plasma should consist of high-
speed centrifugation, eg, 2 × 5 minutes or 1 × 15 minutes 
high-speed centrifugation at 5000 × g. Lower centrifugation 
speeds, eg, 1500 × g, should not be used because contamina-
tion by smaller-sized platelets cannot be ruled out. After the 
first centrifugation step, the samples can either be analyzed 
or stored. A second centrifugation step would follow for a 
short period, eg, centrifugation at 13,000–18,0000 × g for 
two minutes to obtain a microparticle pellet. Applying these 
centrifugation protocols would maintain specificity, while 
sacrificing sensitivity to a certain degree.
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